A tool exists that facilitates the determination of equivalent dosages when transitioning a patient’s treatment from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG) therapy. This resource employs established pharmacokinetic principles and individual patient factors to estimate the appropriate SCIG dose required to maintain a similar therapeutic effect as the prior IVIG regimen. For example, a patient receiving a specific IVIG dose and frequency may require a different, but calculated, SCIG dose and administration schedule to achieve comparable serum immunoglobulin levels.
The utilization of such a tool can be important for optimizing patient care, potentially reducing treatment burden, and enabling greater flexibility in medication administration. Historically, dose conversions relied heavily on empirical data and physician experience. The availability of a calculation aid provides a more systematic and standardized approach, minimizing the risk of under- or over-dosing during the switch from IVIG to SCIG. This, in turn, may improve patient outcomes and adherence to therapy.
